Recombinant CD22 (Pinatuzumab Biosimilar) antibody

Catalog No. ABIN7597912

The Humanized Chimeric anti-CD22 (Pinatuzumab Biosimilar) antibody has been validated for . It is suitable to detect CD22 (Pinatuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD22 (Pinatuzumab Biosimilar) antibody (ABIN7597912)

Target: CD22 (Pinatuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Chimeric

Conjugate: This CD22 (Pinatuzumab Biosimilar) antibody is un-conjugated

Application: Please inquire

Grade: Research Grade

Product Details anti-CD22 (Pinatuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Research Grade Pinatuzumab Biosimilar Antibody

Specificity: Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22

Purification: Protein A or G purified from cell culture supernatant.

Purity: >95 % by SDS-PAGE.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.01M PBS, pH 7.4.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Expiry Date: 12 months

Target Details for CD22 (Pinatuzumab Biosimilar)

Target: CD22 (Pinatuzumab Biosimilar)

Alternative Name: Pinatuzumab Biosimilar

Target Type: Biosimilar

Background: Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22

UniProt: P20273